Group 1 - The medical beauty sector increased by 1.68% on November 11, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4002.76, down 0.39%, while the Shenzhen Component Index closed at 13289.0, down 1.03% [1] - Major stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 160.97, up 2.86%, and Jinbo Biological down 2.00% at 231.20 [1] Group 2 - The net inflow of main funds in the medical beauty sector was 104 million yuan, while retail investors experienced a net outflow of 68.75 million yuan [1] - Specific stock fund flows indicated that Ai Meike had a net outflow of 500.88 million yuan, while Huaxi Biological saw a net inflow of 276.77 million yuan [2] - ST Meigu experienced a significant net outflow of 1.79 million yuan, reflecting a decline of 18.27% [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company achieved a revenue growth of 31% year-on-year for Q1-Q3 2025, driven by new product launches and the multi-faceted empowerment from Yangshengtang [4][5] - The forecasted net profits for the company from 2025 to 2027 are expected to be 879 million, 1.217 billion, and 1.56 billion RMB respectively, with corresponding P/E ratios of 31, 22, and 17 times based on the closing price on November 7, 2025 [5] Financial Performance Summary - For Q1-Q3 2025, the company reported a revenue of 1.296 billion RMB (yoy +31%) and a net profit of 568 million RMB (yoy +9%) [7] - The revenue growth is primarily attributed to the increase in sales of medical devices and functional skincare products, with a notable rise in the sales of A-type recombinant human collagen products [7] - The company’s revenue for 2025 is projected to reach 1.904 billion RMB, with a year-on-year growth rate of 31.98% [6][8] - The gross profit margin is expected to remain high at around 90% for the coming years, indicating strong profitability [8] Product and Market Development - The company launched the new HiveCOL collagen product in July 2025, which is anticipated to drive growth in the medical aesthetics sector [7] - The company is actively expanding its market presence through online promotions and collaborations with both international and domestic brands, enhancing its sales channels [7] - The company has received regulatory approval for its recombinant type III human collagen freeze-dried fibers, which have broad application prospects in various medical fields [7]

Group 1 - The medical beauty sector increased by 4.29% on November 10, with *ST Meigu leading the gains [1] - The Shanghai Composite Index closed at 4018.6, up 0.53%, while the Shenzhen Component Index closed at 13427.61, up 0.18% [1] - The main funds in the medical beauty sector saw a net inflow of 94.61 million yuan, while retail funds experienced a net outflow of 53.71 million yuan [1] Group 2 - *ST Meigu's closing price was 4.22 yuan, with a rise of 4.98% and a trading volume of 163,200 shares, amounting to a transaction value of 68.05 million yuan [1] - Aimeike's closing price was 156.50 yuan, with a rise of 4.92% and a trading volume of 110,400 shares, amounting to a transaction value of 173.27 million yuan [1] - Huaxi Biological's closing price was 51.46 yuan, with a rise of 3.37% and a trading volume of 40,500 shares, amounting to a transaction value of 207 million yuan [1]

Core Viewpoint - The event hosted by Shanghai Shenshi Medical Beauty Hospital focuses on integrating traditional Chinese medicine with skincare, emphasizing the importance of natural, safe, and long-lasting skincare solutions in response to evolving consumer demands [1] Group 1: Event Overview - Shanghai Shenshi Medical Beauty Hospital held a skincare salon themed "Inheriting Traditional Chinese Wisdom, Protecting Skin Health" [1] - The salon attracted executives from multiple listed companies, highlighting its significance in the industry [1] Group 2: Skincare Insights - A senior beauty TCM doctor used the winter solstice as a starting point to educate attendees on skincare, noting that skin tends to become dry and dull during this period, and emphasized the "nourishing and storing" principle [1] - The doctor demonstrated relevant therapies and shared practical daily methods for skincare [1] Group 3: Company Strategy - Shanghai Shenshi Medical Beauty Hospital is a key initiative of Shanghai Industrial (Group) Co., Ltd., aligning with the Healthy China and Healthy Shanghai strategies [1] - The hospital collaborates with experts from Shanghai Jiao Tong University School of Medicine and the Ninth People's Hospital to contribute to the multi-tiered healthcare system in Shanghai and the development of an Asian medical center [1] Group 4: Educational Purpose - The salon serves as a platform for sharing achievements in the field of TCM skincare and aims to educate the public on traditional health and skincare knowledge [1] - The initiative is designed to promote the upgrade of health consumption concepts by integrating traditional wellness practices into daily life [1]

Macro Insights - October CPI turned positive year-on-year, exceeding market expectations, driven by the weakening high base effect, seasonal food price increases, holiday effects, and medical price reforms impacting service prices [2] - PPI recorded its first month-on-month increase this year, attributed to improved supply-demand dynamics in industrial products and rising international metal prices [2] Trade Data - In October 2025, China's exports fell by 1.1% year-on-year, significantly down from the previous month, primarily due to high base effects. Integrated circuits and automobiles were key export drivers, while labor-intensive products contributed negatively [3] - The export growth rate is expected to remain affected by high base effects in the remaining months of the year, but supportive non-US economies and easing US-China trade relations are likely to maintain a favorable export outlook [3] Market Strategy - The current market position is seen as a potential starting point for a long-term bull market, with gradual improvements in fundamentals and industry highlights as the foundation. The inflow of resident funds and policy support will influence market trends [4][10] - The market may enter a wide-ranging consolidation phase in the short term, with a focus on defensive and consumer sectors, while mid-term attention remains on TMT and advanced manufacturing sectors [10] Bond Market - The secondary market for REITs showed a downward trend, with the weighted REITs index closing at 182.3, reflecting a return rate of -0.48% for the week [5] - Credit bond issuance totaled 334 bonds with a total scale of 363.4 billion yuan, a decrease of 7.66% week-on-week, while industrial bonds saw a 5.36% increase in issuance [6] Industry Research TMT Sector - The narrative around AI investments is shifting from "need to invest" to "need for returns," leading to a revaluation of AI visibility and realization. Major tech companies are experiencing accelerated growth in cloud computing revenue, validating AI demand [11] - Recommended stocks include Microsoft, with a focus on Google, Amazon, and Meta [11] Basic Chemicals - Strong demand for energy storage is tightening the supply-demand situation for iron phosphate, leading to improved prices and profitability for leading phosphate chemical companies [12] - Suggested stocks include Yuntianhua, Chuanheng, and Xingfa Group [12] Oil and Gas - OPEC+ announced a pause in production increases, which is expected to alleviate concerns over oil supply. Geopolitical tensions are likely to support oil prices [13] - The report highlights risks related to upstream capital expenditure growth and price volatility [13] Food and Beverage - Recommendations include strong brands with high dividend returns like Kweichow Moutai and Shanxi Fenjiu, as well as companies benefiting from structural upgrades in the beer sector [14] - Suggested stocks include Yihai International and Mengniu Dairy [14] Automotive - The automotive market showed strong performance in October, with NIO's monthly sales surpassing 40,000 units. Recommended stocks include NIO and XPeng Motors [15] - Suggested components include Fuyao Glass and Wuxi Zhenhua [15] Textile and Apparel - The textile and apparel sector is focusing on mitigating tariff impacts and enhancing market share among leading companies. Recommended stocks include Shenzhou International and Anta Sports [16] - The cosmetics sector is expected to highlight the capabilities of leading companies amid intensified competition [16] Company Research Hong Kong Stock Exchange - The company reported record high revenue and profit for the first three quarters of 2025, driven by active trading in the Hong Kong stock market [17] - The forecast for net profit from 2025 to 2027 is 17.3 billion, 18.5 billion, and 19.5 billion HKD, maintaining a "buy" rating [17] Farah Electronics - The company achieved a revenue of 1.445 billion yuan in Q3 2025, with a year-on-year growth of 9.31%. The market share in the new energy sector continues to rise [18] - The stock is rated as a "buy" with a projected PE of 20X, 16X, and 14X for 2025-2027 [18] Huahong Semiconductor - The company is entering a price increase cycle due to sustained demand recovery, with adjusted net profit forecasts for 2025-2027 of 70 million, 150 million, and 190 million USD [19] - The stock is rated as a "buy" based on market share growth and long-term revenue potential [19] Meili Tianyuan Medical Health - The acquisition of Siyanli is expected to enhance the company's performance, with revised net profit forecasts for 2025-2027 of 320 million, 440 million, and 490 million yuan [20] - The stock is rated as a "buy" with a focus on shareholder returns [20]

Group 1 - The North Exchange 50 Index and the Specialized and Innovative Index will undergo adjustments on December 15, 2025, with the North Exchange 50 Index experiencing its fourth adjustment and the Specialized and Innovative Index its first adjustment [10][12][15] - The North Exchange 50 Index closed at 1,522.73 points, reflecting a weekly decline of 3.79%, while the Specialized and Innovative Index closed at 2,532.06 points, down 5.43% [31][32] - The report emphasizes the importance of focusing on high-quality stocks and technology growth within the North Exchange 50 components, particularly those that have undergone significant price adjustments [3][42] Group 2 - The report identifies potential new additions to the North Exchange 50 Index, including companies such as Kaifa Technology, Gobika, and Wantong Hydraulic, with a focus on their average market capitalization and trading volume [12][13] - The North Exchange Specialized and Innovative Index is expected to include companies like Star Map Measurement and Senxuan Pharmaceutical, highlighting their market performance and growth potential [15][16] - The report suggests that the North Exchange's valuation structure shows a significant number of companies with high P/E ratios, indicating a potential investment opportunity in undervalued stocks [21][36][41] Group 3 - The report indicates that the average P/E ratio for key sectors such as high-end equipment, information technology, and chemical new materials are 42.83X, 91.31X, and 48.18X respectively, suggesting varying levels of valuation across industries [36][41] - The North Exchange's market performance shows a decline in trading volume, with an average daily turnover of 230.88 billion yuan, down 20.36% from the previous week [26][30] - The report highlights the importance of monitoring companies with strong quarterly performance and reasonable valuations as the North Exchange approaches its index adjustments [42][43]

Investment Rating - The report assigns a rating of "Buy" to the company [4]. Core Insights - The company has demonstrated strong growth in new orders for Q3 2025, primarily driven by performance in the Chinese, Korean, and Thai markets. The flagship multi-functional device, Alma Harmony, has shown robust growth, contributing to a double-digit year-on-year increase in unaudited revenue for the quarter [1][2]. - The injection filling business has seen a remarkable growth of 218% in the first half of 2025, showcasing strong product capability and channel layout. The long-acting botulinum toxin, DaxibotulinumtoxinA (DAXXIFY), is progressing smoothly towards its expected launch in China [3][19]. - The penetration rate of botulinum toxin in the Chinese market remains below the global average, indicating significant growth potential. The company is well-positioned to capitalize on this opportunity with its DAXXIFY product, which has already seen rapid revenue growth in the U.S. market [4][29]. Summary by Sections Energy Source Equipment - The demand for energy source equipment in the Asia-Pacific market is strong, with new orders showing double-digit growth in Q3. The company’s energy source equipment business has rebounded significantly in Q3 2025 after facing challenges earlier in the year due to high interest rates and geopolitical tensions affecting North America [2][13]. - The flagship device, Alma Harmony, launched globally in March 2025, has received a strong market response, further boosting order volumes. The Soprano series laser devices have also performed well, particularly after the successful launch of "Titan Lift" in China [2][13]. Injection Filling - The injection filling business, particularly the hyaluronic acid products, has shown strong growth, with the company planning to enhance the promotion of Profhilo in Thailand and expand Revanesse sales in the UK, German-speaking regions, Australia, and New Zealand [3][19]. - The anticipated approval and launch of DAXXIFY in September 2024 is expected to inject new growth momentum into the injection filling business [3][19]. Botulinum Toxin - The Chinese botulinum toxin market is projected to grow steadily, with an expected market size of 14.3 billion yuan by 2025, reflecting a CAGR of 26% from 2019 to 2025. The current penetration rate of botulinum toxin in China is significantly lower than the global average, indicating ample room for growth [20][25]. - The company’s DAXXIFY product, which utilizes proprietary peptide exchange technology, is expected to achieve rapid market penetration in China due to its long-lasting effects and high safety profile [29][25]. Financial Forecast and Investment Recommendations - The company is projected to achieve revenues of $382 million, $442 million, and $510 million for 2025, 2026, and 2027, respectively, with corresponding net profits of $29 million, $36 million, and $45 million. The earnings per share (EPS) are expected to be $0.06, $0.08, and $0.10 for the same years [8][36]. - The report emphasizes that the energy source equipment business is expected to stabilize and recover, while the injection filling business is likely to see significant contributions from the upcoming DAXXIFY launch [8][35].

Market Overview - The medical beauty sector experienced a decline of 0.93% on November 7, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1] Stock Performance - The closing prices and performance of key stocks in the medical beauty sector are as follows: - *ST Meigu: Closed at 4.02, up 1.77% with a trading volume of 143,600 shares and a turnover of 57.01 million yuan [1] - Jinbo Biological: Closed at 234.00, up 0.02% with a trading volume of 7,738.5 shares and a turnover of 1.83 billion yuan [1] - Huaxi Biological: Closed at 49.78, down 0.04% with a trading volume of 17,300 shares and a turnover of 86.15 million yuan [1] - Ai Meike: Closed at 149.16, down 1.87% with a trading volume of 30,900 shares and a turnover of 465 million yuan [1] Capital Flow - The medical beauty sector saw a net outflow of 46.6453 million yuan from main funds, while retail investors contributed a net inflow of 34.3979 million yuan [1] - The capital flow for key stocks is as follows: - *ST Meigu: Net outflow of 2.6832 million yuan, down 4.71% [2] - Huaxi Biological: Net outflow of 3.3342 million yuan, down 3.87% [2] - Ai Meike: Net outflow of 40.6279 million yuan, down 8.74% [2]

Investment Rating - The industry investment rating is "Outperform the Market" with an expected relative increase of over 10% in the next six months [25]. Core Insights - The fund allocation ratio for the beauty and personal care industry decreased in Q3 2025, with a total market capitalization of 284.799 billion yuan, reflecting a 2.79% increase from Q2 2025. The fund's total holdings in the beauty and personal care sector amounted to 6.796 billion yuan, resulting in a fund allocation ratio of 0.20%, which is a decrease of 0.12 percentage points from Q2 2025, indicating a continued underweight position [2][11]. - The medical beauty sub-sector is currently in an overweight position, while personal care and cosmetics are underweight. The fund allocation ratio for personal care products was 0.04% in Q3 2025, down 0.04 percentage points from the previous quarter. The cosmetics sector also saw a decline, maintaining a fund allocation ratio of 0.04% in Q3 2025, down 0.02 percentage points [3][16]. - The top three stocks by fund holding in Q3 2025 are Jinbo Biological, Aimeike, and Baiya Shares, with a total holding ratio of 0.07%, which is a decrease of 0.04 percentage points from Q2 2025 [4][18]. Summary by Sections Industry Overview - In Q3 2025, the beauty and personal care industry fund allocation ratio decreased to 0.20%, with an underweight ratio of -0.09%, indicating a continued low allocation [2][11]. Sub-sector Analysis - Medical Beauty: The fund allocation ratio peaked at 0.53% in Q4 2022 but has since declined to 0.12% in Q3 2025, with an overweight ratio of 0.03% in Q2 2025 [3][16]. - Personal Care: The fund allocation ratio was at a historical low from Q3 2021 to Q3 2022, with a slight recovery post-Q4 2022. The current ratio is 0.04%, indicating a shift from positive to negative overweight [3][16]. - Cosmetics: The fund allocation ratio has been declining since Q3 2022, currently at 0.04%, with an overweight ratio of -0.09% [3][16]. Stock Holdings - The top three stocks in the beauty and personal care sector by fund holding in Q3 2025 are Jinbo Biological (0.0254%), Aimeike (0.0195%), and Baiya Shares (0.0051%), all showing a decline in holding ratios compared to Q2 2025 [4][21]. Investment Recommendations - The report suggests focusing on cosmetics and medical beauty sectors due to significant demand potential in the long term, driven by the "beauty economy." It also highlights the importance of compliance and strong R&D capabilities in personal care products [5][24].

Group 1 - The medical beauty sector increased by 0.18% on November 6, with *ST Meigu leading the gains [1] - The Shanghai Composite Index closed at 4007.76, up 0.97%, while the Shenzhen Component Index closed at 13452.42, up 1.73% [1] - The trading volume and turnover for *ST Meigu were 137,900 hands and 53.13 million yuan, respectively, with a price increase of 3.95% [1] Group 2 - The medical beauty sector experienced a net outflow of 34.96 million yuan from main funds, while retail investors saw a net inflow of 36.62 million yuan [1] - Individual stock performances included *ST Meigu with a 3.95% increase, Aimeike with a 0.38% increase, Huaxi Biological with a 0.52% decrease, and Jinbo Biological with a 2.54% decrease [1] - The net fund flow for *ST Meigu was -3.52 million yuan, indicating a decrease of 6.63% [2]